Publication:
Prophylactic Platelets in Dengue: Survey Responses Highlight Lack of an Evidence Base

dc.date.accessioned 2018-09-14T11:15:06Z
dc.date.available 2017-07-12T04:02:24Z
dc.date.available 2012-05-17 en_US
dc.date.available 2012-05-17 en_US
dc.date.available 2012-05-17 en_US
dc.date.available 2012-05-17 en_US
dc.date.available 2012-05-17 en_US
dc.date.available 2012-05-17 en_US
dc.date.available 2012-05-17 en_US
dc.date.available 2012-05-17 en_US
dc.date.available 2018-09-14T11:15:06Z
dc.date.issued 2012-06-01 en_US
dc.description.abstract Dengue is the most important arboviral infection of humans. Thrombocytopenia is frequently observed in the course of infection and haemorrhage may occur in severe disease. The degree of thrombocytopenia correlates with the severity of infection, and may contribute to the risk of haemorrhage. As a result of this prophylactic platelet transfusions are sometimes advocated for the prevention of haemorrhage. There is currently no evidence to support this practice, and platelet transfusions are costly and sometimes harmful. We conducted a global survey to assess the different approaches to the use of platelets in dengue. Respondents were all physicians involved with the treatment of patients with dengue. Respondents were asked that their answers reflected what they would do if they were the treating physician. We received responses from 306 physicians from 20 different countries. The heterogeneity of the responses highlights the variation in clinical practice and lack of an evidence base in this area and underscores the importance of prospective clinical trials to address this key question in the clinical management of patients with dengue.
dc.identifier.uri https://demo7.dspace.org/handle/10673/196
dc.language English en_US
dc.title Prophylactic Platelets in Dengue: Survey Responses Highlight Lack of an Evidence Base en_US
dc.type Journal Article
dspace.entity.type Publication
relation.isAuthorOfPublication b1b2c768-bda1-448a-a073-fc541e8b24d9
Files
Collections